RMC-6236 (Not yet branded)

Description

RMC-6236 is a RAS(ON) inhibitor designed to target active RAS proteins in colorectal cancer patients harboring specific RAS mutations. This compound represents a novel approach to directly inhibiting RAS proteins in their active, GTP-bound state, addressing tumors with KRAS and NRAS mutations that have historically been difficult to target. RMC-6236 is being developed for patients with advanced solid tumors, including colorectal cancer, where RAS mutations drive tumor growth and resistance to standard therapies.

Mechanism of Action

RMC-6236 works by binding to and inhibiting RAS proteins in their active GTP-bound conformation, effectively blocking the oncogenic signaling cascade that promotes tumor cell proliferation and survival. Unlike previous attempts to target RAS indirectly, this compound directly engages the active form of mutant RAS proteins, disrupting downstream signaling pathways including RAF-MEK-ERK and PI3K-AKT that are critical for cancer cell growth.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials